Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.50 |
| ▸ | GALR3 | O60755 | 2/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | DCTPP1 | Q9H773 | 5/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130975 | 0.83 | DCTPP1 (0.51) | PDE10ADCTPP1 | |
| SCHEMBL6492577 | 0.76 | DCTPP1 (0.41) | PDE10AGALR3NR2F2RAB9ADCTPP1 | |
| SCHEMBL6498493 | 0.75 | DCTPP1 (0.40) | PDE10AGALR3NR2F2RAB9ADCTPP1 | |
| SCHEMBL10443033 | 0.75 | TNF (0.51) | PDE10AGALR3NR2F2RAB9ADCTPP1 | |
| SCHEMBL6486764 | 0.73 | DCTPP1 (0.44) | DCTPP1 | |
| SCHEMBL6170123 | 0.72 | TNF (0.58) | GALR3NR2F2RAB9ADCTPP1TNF | |
| SCHEMBL23579650 | 0.71 | TNF (0.50) | PDE10AGALR3NR2F2RAB9ADCTPP1 | |
| SCHEMBL6172987 | 0.71 | SPHK1 (0.59) | GALR3NR2F2RAB9ADCTPP1TNF | |
| SCHEMBL6923116 | 0.70 | DCTPP1 (0.36) | PDE10ADCTPP1TNFALDH1A1MAPK1 | |
| SCHEMBL13714558 | 0.69 | KDM4E (0.62) | GALR3NR2F2RAB9ATNFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6369092-B1 | Method for treating neoplasia by exposure to substituted benzimidazole derivatives | CELL PATHWAYS, INC. | 2002-04-09 | — | — | US | disclosed |